Copyright of Annals of Burns & Fire Disasters is the property of Euro-Mediterranean Council for Burns & Fire Disasters and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Copyright of Revue Francophone des Laboratoires is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Roubertie, A., Roze, E., Bahi-Buisson, N., Payet, C., Echenne, B., and Doummar, D.
Subjects
*TREATMENT of dystonia, *PEDIATRIC therapy, *FOLLOW-up studies (Medicine), *NEUROSURGERY, *DRUG dosage, *DRUG side effects
Abstract
Summary: Dystonia is not uncommon in childhood, but is clinically very heterogeneous. Therefore, introduction and follow-up of the treatment of dystonia in children are often a challenge for the physicians. Progresses in functional neurosurgery have open new fields in the treatment of dystonia in children, but it should be managed by a multidisciplinary team. This paper reviews the various therapeutic options available for childhood-onset dystonia, with a specific attention to dosage and side effects of the drugs regarding pediatric population according to the data of the literature. The rational strategy for therapeutic management of the various types of childhood dystonia is discussed. [Copyright &y& Elsevier]
Abstract: The present paper reports the results of an open 3-month trial of baclofen for the treatment of alcohol dependence. Baclofen was prescribed at escalating dose, with 300mg/day as set upper limit, up to the point at which patients experienced a decrease or a suppression of their motivation to drink. The results show that, at 3months, 88% of the patients had either totally stopped drinking, or had significantly decreased their alcohol intake and that many of them had become indifferent to alcohol, effortlessly. Efficacious doses were highly variable from patient to patient, ranging from 15mg/day to 300mg/day (average 145mg/day). Approximatelaly 2/3 of the patients needed a dose higher than the approved 80mg/day dose. [Copyright &y& Elsevier]